Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome.
Am Heart J. 2011 Jul;162(1):81-8
Authors: Weber M, Bazzino O, Navarro Estrada JL, de Miguel R, S…

[Read more →]

Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials.
Am Heart J. 2011 Mar;161(3):622-630.e1
Author…

[Read more →]

Outcomes in patients with chest pain evaluated in a chest pain unit: The Chest Pain Evaluation in the Emergency Room study cohort.
Am Heart J. 2011 May;161(5):871-7
Authors: Cullen MW, Reeder GS, Farkouh ME, Kopecky SL, Smars …

[Read more →]

Treatment and outcomes in patients with myocardial infarction treated with acute ?-blocker therapy: Results from the American College of Cardiology’s NCDR®.
Am Heart J. 2011 May;161(5):864-70
Authors: Kontos MC, Diercks DB, …

[Read more →]

Treatment and outcomes in patients with myocardial infarction treated with acute ?-blocker therapy: Results from the American College of Cardiology’s NCDR®.
Am Heart J. 2011 May;161(5):864-70
Authors: Kontos MC, Diercks DB, …

[Read more →]

Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization.
Am Heart J. 2011 May;161(5):944-9
Authors: Testani JM, Cappola TP, McCauley…

[Read more →]

Impact of contrast-induced acute kidney injury definition on clinical outcomes.
Am Heart J. 2011 May;161(5):963-71
Authors: Budano C, Levis M, D’Amico M, Usmiani T, Fava A, Sbarra P, Burdese M, Segoloni GP, Colombo A, Marra S
…

[Read more →]

Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG).
Am Heart J. 2011 Feb;161(2):418-424…

[Read more →]

Ultrafiltration in heart failure.
Am Heart J. 2011 Mar;161(3):439-49
Authors: Fiaccadori E, Regolisti G, Maggiore U, Parenti E, Cremaschi E, Detrenis S, Caiazza A, Cabassi A
Fluid overload is a key pathophysiologic mec…

[Read more →]

Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions.
Am Heart J. 2011 Mar;161(3):450-61
Authors: White HD
Despite the proven efficacy of dual antiplatelet therapy with aspirin an…

[Read more →]

High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration.
…

[Read more →]

Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship.
Am Heart J. 2011 Mar;161(3):567-73
Authors: Ather S, Chan W, Chillar A, Aguilar D, Pr…

[Read more →]

Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients.

Am Heart J. 2011 Feb;161(2):241-6

Authors: Sellers MB, Newby LK

Atrial fibrillation (AF) affects 2.5 million patients in the United States. The incidence of this condition increases with age, such that approximately 5% of people >65 years of age have AF. Because of the lack of organized atrial contraction and thrombus formation in the left atrium, patients with AF are at increased risk of stroke. The estimated risk of stroke among all AF patients is 5% per year. Among patients without mitral stenosis, there is a graded relationship of stroke risk with the number of CHADS(2) risk factors. Warfarin is the recommended treatment for embolic stroke prophylaxis in AF in intermediate- to high-risk patients. However, elderly patients who are deemed to be at risk of falls are often not started on warfarin therapy secondary to a perceived higher risk of bleeding complications. These risks have been evaluated, but conclusive data regarding the risk-benefit trade-off are elusive. This review summarizes available data on the use of warfarin in elderly patients with AF, focusing on the risk of bleeding, and will specifically address the utility of falls risk assessment in the decision to initiate warfarin therapy for AF.

PMID: 21315204 [PubMed - in process]

[Read more →]

Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

Am Heart J. 2011 Feb;161(2):298-306.e1

Authors: Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW

The aim of the study was to investigate the incidence and clinical consequences of acquired thrombocytopenia in patients with acute coronary syndromes (ACS) in the ACUITY trial.

PMID: 21315212 [PubMed - in process]

[Read more →]

Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: A subgroup analysis of the randomized, controlled CERTIFY study.

Am Heart J. 2011 Feb;161(2):322-8

Authors: Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, Bramlage P, Riess H

Despite the elevated risk for developing venous thromboembolic events in patients with heart failure, there are no randomized, double-blind, controlled trial data on the comparison of low-molecular-weight heparin with unfractionated heparin (UFH) in this patient population.

PMID: 21315215 [PubMed - in process]

[Read more →]